TW200716208A - Modified and immediate release memantine bead formulation - Google Patents

Modified and immediate release memantine bead formulation

Info

Publication number
TW200716208A
TW200716208A TW095121264A TW95121264A TW200716208A TW 200716208 A TW200716208 A TW 200716208A TW 095121264 A TW095121264 A TW 095121264A TW 95121264 A TW95121264 A TW 95121264A TW 200716208 A TW200716208 A TW 200716208A
Authority
TW
Taiwan
Prior art keywords
modified
immediate release
dosage forms
bead formulation
release memantine
Prior art date
Application number
TW095121264A
Other languages
English (en)
Inventor
Mahendra G Dedhiya
Suneel K Rastogi
Anil Chhettry
Narasimhan Mani
Antonia Periclou
Niranjan Rao
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of TW200716208A publication Critical patent/TW200716208A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095121264A 2005-06-16 2006-06-14 Modified and immediate release memantine bead formulation TW200716208A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69151205P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
TW200716208A true TW200716208A (en) 2007-05-01

Family

ID=37025104

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095121264A TW200716208A (en) 2005-06-16 2006-06-14 Modified and immediate release memantine bead formulation

Country Status (10)

Country Link
US (6) US20070065512A1 (zh)
EP (1) EP1898890A1 (zh)
JP (1) JP2008543845A (zh)
AR (1) AR054139A1 (zh)
AU (1) AU2006259619A1 (zh)
CA (1) CA2607600A1 (zh)
EA (1) EA013474B1 (zh)
TW (1) TW200716208A (zh)
WO (1) WO2006138227A1 (zh)
ZA (1) ZA200710270B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2008005036A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
CN113143901A (zh) 2007-03-22 2021-07-23 纽罗森特里亚股份有限公司 镁组合物及其用途
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
AU2010300475A1 (en) 2009-09-30 2012-05-03 The Regents Of The University Of California Cofactors and methods for use for individuals
EP2585049A1 (en) * 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
EP2627323A4 (en) 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
CN102552218A (zh) * 2010-12-31 2012-07-11 无锡万全医药技术有限公司 一种盐酸美金刚胶囊缓释剂及其制备方法
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
EP2675435A1 (en) * 2011-02-17 2013-12-25 Lupin Limited Sustained release composition of memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
CN103181914B (zh) * 2011-12-27 2014-11-05 上海复星医药产业发展有限公司 盐酸美金刚缓释胶囊及其制备方法
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
ES2623176T3 (es) 2012-08-16 2017-07-10 Teva Pharmaceutical Industries Ltd. Composición farmacéutica de memantina
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
CN104013592B (zh) * 2014-06-10 2017-12-15 浙江京新药业股份有限公司 盐酸美金刚缓释药丸及其制备方法
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
MX395015B (es) 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
ES2763321T3 (es) * 2015-12-23 2020-05-28 Laboratorios Bago S A Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes
EP4556457A3 (en) 2016-06-15 2025-06-18 Ojai Energetics PBC Methods and compositions for potentiating stem cell therapies
NZ749229A (en) 2016-06-15 2026-01-30 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress
JP6420508B2 (ja) * 2017-02-10 2018-11-07 大原薬品工業株式会社 化学的な安定性が改善された、メマンチン塩酸塩を含有する製剤
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
WO2018213838A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
DK3638211T3 (da) * 2017-06-14 2024-01-22 SpecGx LLC Farmaceutiske sammensætninger med forsinket vedvarende frigivelse
CN108969506A (zh) * 2018-09-11 2018-12-11 山东鲁抗医药股份有限公司 一种盐酸美金刚缓释微丸及其制备方法
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
CN109172538A (zh) * 2018-10-25 2019-01-11 安徽鼎旺医药有限公司 一种盐酸美金刚速溶微丸软胶囊
MX2021004586A (es) 2018-11-19 2021-06-15 Supernus Pharmaceuticals Inc Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada.
GB2615034A (en) 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
CN113546063A (zh) * 2020-04-26 2021-10-26 江苏天士力帝益药业有限公司 一种盐酸美金刚缓释胶囊及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
KR100630506B1 (ko) * 1997-06-30 2006-09-29 메르츠 파마 게엠베하 운트 코. 카가아 Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6413556B1 (en) * 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
BR0109602A (pt) * 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations

Also Published As

Publication number Publication date
AU2006259619A1 (en) 2006-12-28
ZA200710270B (en) 2008-12-31
EA200800064A1 (ru) 2008-04-28
US20070065512A1 (en) 2007-03-22
US20130302430A1 (en) 2013-11-14
US20130011474A1 (en) 2013-01-10
CA2607600A1 (en) 2006-12-28
EP1898890A1 (en) 2008-03-19
WO2006138227A1 (en) 2006-12-28
EA013474B1 (ru) 2010-04-30
AR054139A1 (es) 2007-06-06
JP2008543845A (ja) 2008-12-04
US20150258042A1 (en) 2015-09-17
US20120201889A1 (en) 2012-08-09
US20160346227A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
TW200716208A (en) Modified and immediate release memantine bead formulation
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
ATE451340T1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
SE0203817D0 (sv) New composition
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
WO2008034895A3 (en) Ansamycin derivatives
MX2009001631A (es) Formulacion farmaceutica para el tratamiento de afecciones en la piel.
MD2904G2 (ro) Utilizarea preparatului Gerovital H3 pentru tratamentul afecţiunilor sistemului nervos central la copii
MY154883A (en) A combination composition
UA87224C2 (ru) Применение 24-нор-урсодеоксихолевой кислоты для лечения холестатических заболеваний печени
HK1121756A (zh) 取代2-氨基嘧啶-4-酮、其药物组合物及其在治疗或预防Aβ相关病症中的用途
ITRA20050012U1 (it) Apparecchio cosmetico elettronico per la cura e la prevenzione dell'acne con emissioni uv e micromagneto terapia.
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом